CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond","$":{"href":"/biotech/ausperbio-adds-120m-advance-hepatitis-b-therapy-through-ph3-and-commercialization","hreflang":"en"}}]}

Positive
AI Analysis

Summary

AusperBio Therapeutics raised $120 million in Series C funding to advance its oligonucleotide therapy for chronic hepatitis B through Phase 3 testing and commercialization.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.70
FinancingSeries COligonucleotideHepatitis BPhase 3

Read the original article

Published by FierceBiotech on August 28, 2026 10:30 AM

Read Original